“If I am a female and I look at the male team members around me becoming fathers and none of them take any parental leave, I will feel that I am an outlier when I get pregnant and I need my parental leave,” says Chief Operating Officer Morten Welo. “So we thought - ‘let’s turn this around’, and say it’s mandatory regardless of gender.”
GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.
The Carlsbad, Calif.-based firm said that its board of directors has appointed Hany Massarany as its new president and CEO. Massarany has served as president of Ventana Medical Systems and Head of Roche Tissue Diagnostics since February 2009. He spent 10 years at Ventana in various executive positions, including COO and EVP of worldwide operations. Ventana was acquired by Roche in February 2008 for around $3.4 billion.
Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board.
"Xcell Biosciences created the Technology Access Program (TAP) to accelerate the discovery of novel applications using our proprietary Primary Cell Control Systems in the field of Immunotherapy. We launched the TAP to collaborate with researchers and commercial partners in advancing the technology frontier of Human Microenvironments (HME) including Tumor Microenvironments (TME). We will provide the instrumentation and technical support necessary for partners to jointly invent and validate new discovery technology," said Janette Phi, COO. "Our solutions focus on clinical researchers developing therapies at the convergence of precision medicine, stem cell technology, and immunotherapy."